Your browser doesn't support javascript.
loading
Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor.
Lee, Seung-Yul; Cho, Jae Young; Gorog, Diana A; Angiolillo, Dominick J; Yun, Kyeong Ho; Ahn, Jong-Hwa; Koh, Jin-Sin; Park, Yongwhi; Hwang, Seok-Jae; Hwang, Jin-Yong; Kim, Jin Won; Jang, Yangsoo; Jeong, Young-Hoon.
Afiliação
  • Lee SY; Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea.
  • Cho JY; Multimodal Imaging and Theranostic Laboratory, Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
  • Gorog DA; Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Republic of Korea.
  • Angiolillo DJ; Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Yun KH; Centre for Health Services Research, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
  • Ahn JH; Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, United States.
  • Koh JS; Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Republic of Korea.
  • Park Y; Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
  • Hwang SJ; Department of Internal Medicine, Gyeongsang National University School of Medicine and Division of Cardiology, Gyeongsang National University Hospital, Jinju, Republic of Korea.
  • Hwang JY; Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
  • Kim JW; Department of Internal Medicine, Gyeongsang National University School of Medicine and Division of Cardiology, Gyeongsang National University Hospital, Jinju, Republic of Korea.
  • Jang Y; Department of Internal Medicine, Gyeongsang National University School of Medicine and Division of Cardiology, Gyeongsang National University Hospital, Jinju, Republic of Korea.
  • Jeong YH; Multimodal Imaging and Theranostic Laboratory, Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.
Front Med (Lausanne) ; 11: 1349577, 2024.
Article em En | MEDLINE | ID: mdl-38841588
ABSTRACT

Background:

In patients undergoing percutaneous coronary intervention (PCI), the use of anti-inflammatory therapy with colchicine is associated with a reduction of recurrent ischemic events. The mechanisms of such findings are not fully elucidated.

Objectives:

To investigate the effects of colchicine versus aspirin on inflammation and platelet reactivity in patients with acute coronary syndrome (ACS) undergoing PCI.

Methods:

This observational study compared laboratory measurements in ACS patients receiving single antiplatelet therapy with ticagrelor or prasugrel plus colchicine (MACT) (n = 185) versus conventional dual-antiplatelet therapy (DAPT) with aspirin plus ticagrelor or prasugrel (n = 497). The primary outcome was the frequency of high residual inflammation, defined as high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L at 1 month post-PCI. Multiple sensitivity analyses were performed for the primary outcome, including multivariable adjustment, propensity-score matching, and inverse-probability weighted methods.

Results:

One month after PCI, patients treated with MACT had significantly lower levels of hs-CRP compared to those treated with DAPT (0.6 [0.4-1.2] vs. 0.9 [0.6-2.3] mg/L, p < 0.001). The frequency of high residual inflammation was also lower in the MACT group (10.8% vs. 27.2%, p < 0.001) (odds ratio [95% confidence interval] = 0.33 [0.20-0.54], p < 0.001). This effect was consistent across sensitivity analyses. There was no difference in platelet reactivity between MACT and DAPT (49.6 ± 49.0 vs. 51.5 ± 66.4 P2Y12 reaction unit [PRU] measured by VerifyNow, p = 0.776).

Conclusion:

In ACS patients undergoing PCI, MACT was associated with a lower rate of high residual inflammation without increasing platelet reactivity compared to conventional DAPT. Clinical trial registration NCT04949516 for MACT pilot trial and NCT04650529 for Gyeongsang National University Hospital registry.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article